OPKO Health, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
OPKO Health, Inc. (OPK) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2024-03-01
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2023-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2023-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.14M.
- 2022-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.04M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.14M 10-Q · filed 2023-08-03 |
| 2022-12-31 | $1.04M 10-K · filed 2024-03-01 |
| 2021-12-31 | $2.84M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |